REG - C4X Discovery - MALT-1 Inhibitor Programme Update

C4X Discovery HoldingsAnnouncement

19/01/2023 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20230119:nRSS1829Na&default-theme=true

RNS Number : 1829N  C4X Discovery Holdings PLC  19 January 2023

C4X Discovery Holdings plc

 

("C4XD", "C4X Discovery" or the "Company")

 

MALT-1 Inhibitor Programme Update

 

Positive key preclinical study positions programme for partnering

 

19 January 2023 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug
Discovery company, provides an update on its MALT-1 inhibitor programme.
Over-expression or over-activation of MALT-1 has been observed in a range of
lymphomas and leukemias such as MALT lymphoma, diffuse large B-cell lymphoma
and chronic lymphocytic leukemia, suggesting that targeting of MALT-1 is a
viable therapeutic strategy for treating haematological cancers.

 

Building on promising in vitro, in vivo and pharmacokinetic data, C4XD has now
successfully demonstrated anti-cancer activity for one of its lead molecules
in a preclinical xenograft study. Following oral dosing at 30mg/kg,
significant tumour growth inhibition was observed. This result is comparable
to data obtained from Johnson & Johnson's clinical compound JNJ-67856633
which is now in a Phase I clinical trial. The C4XD MALT-1 inhibitor programme
has now advanced into the preclinical candidate selection phase.

 

MALT-1 is one of the key regulators of B-cell receptor (BCR) and T-cell
receptor (TCR) signalling. Mutations that lead to constitutive activation of
MALT-1 are associated with aggressive forms of non-Hodgkin B-cell lymphoma and
inhibition of MALT-1 has potential therapeutic applicability as a mono therapy
for MALT-1-driven cancers and in combination with BTK inhibitors across
multiple haematological indications, as well as broader potential in solid
tumours and inflammation.

 

Dr Nick Ray, CSO of C4XD, said: "Using our NMR-based 'shapes in solution'
technology, Conformetrix, led to the generation of a number of
structurally-distinct series, now in Lead Optimisation. Showing activity
comparable to the industry's lead clinical compound with our first compound in
this key xenograft model, coupled with the range of improved compounds
following behind, gives us confidence in nominating candidate-quality
molecules within the next six months.

 

"At C4XD we have a reputation for producing high quality small molecule
candidates as seen in our recent out-licensing agreement with AstraZenca worth
up to $401 million. MALT-1 is a highly desirable target for an oral
therapeutic and this study is a key trigger to initiate early-stage
conversations with potential partners in the pharmaceutical industry in order
to maximise the value of this programme."

 

- Ends -

 

Contacts

 

 C4X Discovery Holdings
 Mo Noonan, Communications                                 +44 (0)787 6444977

 Panmure Gordon (UK) Limited (NOMAD and Broker)
 Freddy Crossley, Emma Earl (Corporate Finance)            +44 (0)20 7886 2500
 Rupert Dearden (Corporate Broking)

 C4X Discovery Media - Consilium Strategic Communications
 Mary-Jane Elliott, Chris Gardner, Matthew Neal            +44 (0)203 709 5700

 

Notes to Editors:

 

About C4X Discovery

C4X Discovery ("C4XD") is a pioneering Drug Discovery company combining
scientific expertise with cutting-edge Drug Discovery technologies to
efficiently deliver world leading medicines, which are developed by our
partners for the benefit of patients. We have a highly valuable and
differentiated approach to Drug Discovery through our enhanced DNA-based
target identification and candidate molecule design capabilities, generating
small molecule drug candidates across multiple disease areas including
inflammation, oncology, neurodegeneration and addictive disorders. Our
commercially attractive portfolio ranges from early-stage novel target
opportunities to late-stage Drug Discovery programmes ready for out-licensing
to partners and we have three commercially partnered programmes with one
candidate in clinical development.

 

We collaborate with leading pharmaceutical and life sciences companies to
enrich our expertise and take our assets through pre-clinical and clinical
development. Through early-stage revenue-generating licensing deals, we
realise returns from our high value pre-clinical assets which are reinvested
to maximise the value of our Drug Discovery portfolio.  For further
information see www.c4xdiscovery.com (http://www.c4xdiscovery.com)

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  UPDZZGMMNRVGFZM